Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Plasma from recovered patients tested against COVID-19 – trial ends early

NCT ID NCT04516811

Disease control Sponsor: South African National Blood Service Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving plasma (the liquid part of blood) from people who recovered from COVID-19 could help hospitalized patients with moderate to severe COVID-19. The plasma contains antibodies that might fight the virus. The trial planned to enroll many patients but was stopped early after including 102 adults. Participants received either the plasma or a placebo (salt water) along with standard care. The main goal was to see if more patients improved within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COVID-19 convalescent plasma (antibodies from recovered patients)
What this could lead to
If it worked, this could provide a treatment option for hospitalized COVID-19 patients using donated antibodies.
What could go wrong
The trial was terminated early with only 102 participants, so results are limited. Convalescent plasma carries risks like allergic reactions or lung injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

102 people

The number who actually took part.

Started

Sep 2020

Finished

Jul 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Laboratory confirmed SARS-CoV-2 by positive RT-PCR on any respiratory sample; * Age ≥ 18 years; * Require hospital admission for COVID-19 pneumonia as defined by the presence of pulmonary infiltrates on chest x-ray; * Moderate to severe Covid-19 disease, defined as: SpO2 ≤ 93% on room air; plus requiring non-invasive oxygen therapy (WHO R\&D BOSCI 4 or 5 * Signed informed consent; * Pregnant women will be allowed to participate. Exclusion Criteria: * Current participation in another therapeutic clinical trial for COVID-19; * Invasive mechanical ventilation; * Expected survival \< 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); * Known hypersensitivity to immunoglobulin or any components of the formulation;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 SARS-CoV-2 infection Severe acute respiratory syndrome coronavirus 2

Contacts and locations

Locations

  • Mitchells Plain Hospital

    Cape Town, Western Cape, 7786, South Africa

  • Universitas Hospital

    Bloemfontein, Free State, 9301, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.